# Study of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Progeria

> **NCT00916747** · PHASE2 · UNKNOWN · sponsor: **Boston Children's Hospital** · enrollment: 85 (actual)

## Conditions studied

- Progeria

## Interventions

- **DRUG:** Lonafarnib, Zoledronic Acid, and Pravastatin

## Key facts

- **NCT ID:** NCT00916747
- **Lead sponsor:** Boston Children's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2009-08
- **Primary completion:** 2022-02
- **Final completion:** 2023-12
- **Target enrollment:** 85 (ACTUAL)
- **Last updated:** 2023-02-27

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00916747

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00916747, "Study of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Progeria". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00916747. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*